Talitha Shkopiak is a counsel in Goodwin’s Life Sciences group. She specializes in advising on commercial agreements relating to the creation and commercialization of intellectual property rights, and has particular experience acting for biotechnology companies. Her work ranges from the structuring of development and collaboration agreements for early stage companies, through the completion of complex global licensing and commercialization deals; and includes advising on settlement of patent disputes, intellectual property aspects of corporate transactions, and early stage contract disputes.

Prior to joining Goodwin in 2019, Ms. Shkopiak was a senior associate at Taylor Wessing LLP.

Areas of Practice
Domaines D’Expertise





Acted for MiNA Therapeutics on their Research and Collaboration Agreement with Eli Lilly and Company (a leading pharmaceutical company) under which MiNA would utilize its platform technology for the discovery of novel small activating RNA compounds to identify compounds directed to up to five targets selected by Lilly. 

Acted for Kymab Limited on their strategic partnership with LifeArc (a leading UK medical research charity) under which Kymab would receive a US$30 million equity investment and downstream revenues in connection with granting LifeArc access to Kymab's advanced suite of antibody discovery technologies.

Acted for TxCell SA on a research collaboration with, and subsequent commercialization license from, the University of British Columbia, in relation to cell therapy for prevention of chronic transplant rejection.

Acted for Oxford Biomedica plc on the grant to Axovant Sciences of an exclusive worldwide license in respect of Biomedica’s gene therapy for Parkinson’s disease, under which Biomedica would receive US$30 million upfront and additional revenue.

Acted for Plethora Solutions Limited on the licensing to Wanbang Pharmaceutical of commercialization rights in China for Fortacin™, whilst retaining full commercialization rights in all other territories.

Acted for Oxford Biomedica plc in relation to a collaboration agreement with the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations for the development of a gene therapy product manufacturing process and concurrent option and license agreement for commercialization by Boehringer Ingelheim.

Acted for Artios Pharma Ltd. in relation to a research collaboration with Masaryk University for the development of novel cancer treatments with an option to commercialization rights.

Acted for Oxford Biomedica plc on the collaboration and license agreement with Novartis pursuant to which Oxford Biomedica will receive ongoing royalties from sales of Novartis' product Kymriah – the first CAR-T cell therapy to be approved by the FDA.

Professional Experience

Ms. Shkopiak has undertaken secondments at a London university technology transfer arm and a large pharmaceutical company, giving her broad insight into the sector and the challenges faced by her clients.

Before qualifying in the UK, Ms. Shkopiak qualified and practiced in New Zealand as a patent attorney.


Ms. Shkopiak was recognized by Legal 500 UK in 2021 and 2020 as a Rising Star in the Biotechnology in Cambridge category.

In The News









B.S., Computer Science, 2004
Victoria University of Wellington, New Zealand
Bachelors of Law, 2004
Victoria University of Wellington, New Zealand
(First Class Honours)



Solicitor of the Senior Courts of England and Wales
High Court of New Zealand
Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique